CRBP Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -2301.55%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 409.43%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 27.66%. Given that Corbus Pharmaceuticals Holdings, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Corbus Pharmaceuticals Holdings, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.769, which suggesting that the stock is 176.879% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 58.48x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -12425.36%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 409.43%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 333.37%. Given that Corbus Pharmaceuticals Holdings, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Corbus Pharmaceuticals Holdings, Inc. is more attractive than Perspective Therapeutics, Inc..

Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.769, which suggesting that the stock is 176.879% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 192.56x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of 12.65%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Electromed, Inc.'s return on equity of 18.89%.

Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 409.43%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25%. Given that Corbus Pharmaceuticals Holdings, Inc. has higher upside potential than Electromed, Inc., analysts believe Corbus Pharmaceuticals Holdings, Inc. is more attractive than Electromed, Inc..

Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.769, which suggesting that the stock is 176.879% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 3.84x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of 13.19%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 409.43%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 431.4%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Corbus Pharmaceuticals Holdings, Inc..

Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.769, which suggesting that the stock is 176.879% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 29.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 2.63x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.